Expression of Potential Antibody-Drug Conjugate Targets in Cervical Cancer

Area of Science:

• Oncology
• Molecular Biology
• Immunotherapy

Background:

• Advanced and recurrent cervical cancer present a significant unmet clinical need for new treatments.
• Antibody-drug conjugates (ADCs) are emerging as a promising therapeutic strategy, targeting cancer-specific cell membrane-bound molecules.
• Identifying novel ADC targets is crucial for improving treatment outcomes.

Purpose of the Study:

• To evaluate the expression of ten potential antibody-drug conjugate (ADC) targets at the gene and protein levels in cervical cancer.
• To identify suitable ADC targets for clinical research in advanced and recurrent cervical cancer.
• To provide data to guide the development of future ADC-based therapies.

Main Methods:

• Gene expression analysis was performed for ten potential ADC targets: TROP2, mesotheline, CEACAM5, DLL3, folate receptor alpha, guanylatcyclase, glycoprotein NMB, CD56, CD70, and CD138.
• Protein expression analysis was conducted for the top three identified ADC targets: TROP2, CEACAM5, and CD138.
• Cervical cancer samples were analyzed to quantify target expression levels.

Main Results:

• TROP2 demonstrated high expression in 98.5% of cervical cancer samples.
• CEACAM5 was found to be expressed in 68.7% of samples, with 34.3% showing moderate to high expression.
• CD138 was positive in 73.1% of samples, with 38.8% exhibiting moderate to high expression.

Conclusions:

• TROP2, CEACAM5, and CD138 are identified as suitable targets for antibody-drug conjugate (ADC) development in cervical cancer.
• The high expression rates of these targets support their further investigation in clinical trials.
• This research provides valuable data to inform the design of future ADC therapies for patients with advanced and recurrent cervical cancer.